GH Secretagogues
GHRP-2
Also published as Pralmorelin, KP-102
A synthetic hexapeptide secretagogue. It is registered in Japan as a diagnostic agent for assessing growth hormone secretory capacity, which makes it one of the few compounds here with a real regulatory identity.
Where it came from
Developed from the growth hormone releasing peptide series pioneered by Cyril Bowers, and approved in Japan as a diagnostic.
What the literature examines
- Growth hormone release in diagnostic testing in humans
- Ghrelin receptor pharmacology
- Appetite and food intake in animal models
- Cortisol and prolactin release alongside growth hormone
State of the evidence
Approved in Japan as a diagnostic agent, meaning single administration under supervision to provoke a measurable hormone response.
What a buyer should know
Approval as a diagnostic provocation agent is not approval as a therapy. That distinction gets flattened constantly in vendor copy. Nothing about a one time diagnostic use establishes a safety profile for repeated administration.
Handling and stability
Lyophilised, water soluble.
Read it yourself
We do not publish a curated citation list, because a hand picked list of papers is a sales tool. These links run a live query against the public databases, so you see everything, including the results that do not suit us.
Supplied for laboratory research use only. Nothing on this page is a dose, a protocol or a claim of effect in humans, and nothing here is medical advice. Read our research use policy.